Home » Stocks » RCUS

Arcus Biosciences, Inc. (RCUS)

Stock Price: $36.98 USD -1.85 (-4.76%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 2.40B
Revenue (ttm) 77.78M
Net Income (ttm) -87.60M
Shares Out 62.60M
EPS (ttm) -1.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $36.98
Previous Close $38.83
Change ($) -1.85
Change (%) -4.76%
Day's Open 39.03
Day's Range 34.83 - 40.01
Day's Volume 939,455
52-Week Range 8.78 - 40.01

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 day ago

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today presented prelimina...

Business Wire - 4 days ago

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the ...

Business Wire - 5 days ago

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that prel...

Business Wire - 1 week ago

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Andr...

Zacks Investment Research - 1 week ago

Investors need to pay close attention to Arcus Biosciences (RCUS) stock based on the movements in the options market lately.

Business Wire - 1 month ago

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the ...

Business Wire - 1 month ago

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, and WuXi Biologics (2269....

Business Wire - 1 month ago

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that mana...

Business Wire - 2 months ago

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the ...

Business Wire - 2 months ago

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced financial...

Business Wire - 2 months ago

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced a collabo...

Other stocks mentioned: AZN
Business Wire - 3 months ago

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Jenn...

Business Wire - 4 months ago

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc.

Business Wire - 5 months ago

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc.

Business Wire - 5 months ago

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc.

Business Wire - 5 months ago

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc.

Zacks Investment Research - 5 months ago

Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Seeking Alpha - 6 months ago

Arcus Biosciences, Inc.: An Oncology Stock With Newfound Prominence

Business Wire - 6 months ago

FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS), an oncology-focused biopharmaceutical company working to ...

Business Wire - 6 months ago

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Bob ...

Zacks Investment Research - 6 months ago

Is (RCUS) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 7 months ago

Is (RCUS) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 7 months ago

Arcus Biosciences (RCUS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

The Motley Fool - 7 months ago

The development-stage biopharma is bouncing back from a recent stock dip.

The Motley Fool - 7 months ago

Investors expecting a buyout offer were disappointed by the collaboration agreement Gilead Sciences offered.

The Motley Fool - 7 months ago

The deal gives Gilead access to a new pipeline of potential cancer immunotherapies.

Other stocks mentioned: GILD
Zacks Investment Research - 8 months ago

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -12.50% and -12.50%, respectively, for the quarter ended March 2020.

Zacks Investment Research - 8 months ago

Is (RCUS) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 8 months ago

Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Market Watch - 9 months ago

Shares of Arcus Biosciences Inc. RCUS, +88.44% soared 87% in trading on Thursday after people familiar with the matter told Bloomberg News that Gilead Sciences Inc.

The Motley Fool - 9 months ago

The two companies are apparently discussing either an equity purchase or some other form of cooperation.

Other stocks mentioned: GILD
Investors Business Daily - 9 months ago

Arcus Biosciences stock rocketed to a record high Thursday on reports suggesting Gilead Sciences could be interested in acquiring a stake in the Alphabet-backed biotech company.

Zacks Investment Research - 9 months ago

Does Arcus Biosciences, Inc. (RCUS) have what it takes to be a top stock pick for momentum investors?

The Motley Fool - 9 months ago

Arcus Biosciences stock is on fire in response to a possible partnership deal with Gilead Sciences.

Zacks Investment Research - 9 months ago

Arcus Biosciences (RCUS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

Seeking Alpha - 10 months ago

Arcus Biosciences Anti-TIGIT Candidate Puts Company In The Shop Window

Zacks Investment Research - 10 months ago

Top Ranked Momentum Stocks to Buy for March 13th

Other stocks mentioned: BCYC, GSX, VIRT
The Motley Fool - 10 months ago

Efforts to contain COVID-19 are putting the entire biopharmaceutical industry in a jam.

Other stocks mentioned: BIIB
The Motley Fool - 10 months ago

The coronavirus induced sell-off has created a number of attractive buying opportunities.

Other stocks mentioned: ABBV, AGEN, APHA, BCEL, BCYC, BMY, CPRX, CRNX, FOLD, GWPH, OGI, PFE, SRPT
Zacks Investment Research - 10 months ago

Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

The Motley Fool - 10 months ago

Can these high-flying biotech stocks keep up their sizzling momentum?

Other stocks mentioned: ABEO, AVDL
Zacks Investment Research - 1 year ago

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -8.51% and 30.60%, respectively, for the quarter ended September 2019.

GuruFocus - 1 year ago

CEO of Arcus Biosciences Inc (NYSE:RCUS) Terry J Rosen bought 21,738 shares of RCUS on 06/06/2019 at an average price of $7.93 a share.

GuruFocus - 1 year ago

CEO of Arcus Biosciences Inc (NYSE:RCUS) Terry J Rosen bought 41,540 shares of RCUS on 06/04/2019 at an average price of $7.91 a share.

Zacks Investment Research - 1 year ago

Arcus (RCUS) is expected to provide an update on its pipeline with the release of its first-quarter 2019 results

Seeking Alpha - 1 year ago

ARCUS gene editing platform may be more specific and have less off-target side effects than CRISPR/Cas9.

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Arcus Biosciences, Inc. (RCUS).

About RCUS

Arcus Biosciences, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer therapies in the United States. The company's product pipeline includes, AB928, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 monoclonal antibody that is in Phase Ib clinical trial for monotherapy. It is also developing AB154, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in... [Read more...]

Industry
Biotechnology
IPO Date
Mar 15, 2018
CEO
Dr. Terry J. Rosen Ph.D.
Employees
139
Stock Exchange
NYSE
Ticker Symbol
RCUS
Full Company Profile

Financial Performance

In 2019, RCUS's revenue was $15.00 million, an increase of 79.58% compared to the previous year's $8.35 million. Losses were -$84.71 million, 70.8% more than in 2018.

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for RCUS stock is "Strong Buy." The 12-month stock price forecast is 42.00, which is an increase of 13.57% from the latest price.

Price Target
$42.00
(13.57% upside)
Analyst Consensus: Strong Buy